Evotec and Harvard University to collaborate on development of new class of antibacterials

17-May-2013 - Germany

Revolutionize your production: real-time Raman analysis for maximum efficiency

Efficient inline analysis for liquids and solids

User-friendly software for effortless Design of Experiments (DoE)

Evotec AG announced a research collaboration with Harvard University aimed at discovering and developing novel anti-bacterial agents based on a highly validated target family involved in bacterial cell wall biosynthesis.

Under the Agreement, researchers at Harvard and Evotec will collaboratively identify and optimize small molecule inhibitors of bacterial cell wall synthesis, based on enabling technologies and chemical starting points licensed from Harvard.

"We are pleased to have entered into this collaboration with Harvard in the antibacterial space", said Dr Werner Lanthaler, CEO of Evotec. "The lack of new antibacterials has been broadly recognised as a major unmet medical need as antibiotics pipelines are drying up while resistance against existing drugs is on the rise. We are excited to team up with our colleagues at Harvard to systematically target a highly validated but under-exploited anti-bacterial target family.'"

https://www.bionity.com/en/news/143112/evotec-and-harvard-university-to-collaborate-on-development-of-new-class-of-antibacterials.html